Medical/Pharmaceuticals
Mentice publishes the company's year-end report for the period January-December 2020
STOCKHOLM, Feb. 4, 2021 /PRNewswire/ -- Strong order intake and substantial improvement of the company's order book as well as operating cash flow Fourth quarter (October-December 2020) * Order intake amounted to 73.1 (54.7) MSEK. * Net sales amounted to 45.9 (60.2) MSEK. * Ope...
2021-02-04 16:08
1427
Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B
SINGAPORE, Feb. 4, 2021 /PRNewswire/ -- Gilead Sciences announced today at the 2021 Asian Pacific Association for the Study of the Liver Conference (APASL), findings from two sub-analyses that demonstrated the continued efficacy and improved safety of Vemlidy® (tenofovir alafenamide 25 mg, TAF) ...
2021-02-04 12:00
4251
NCCN Gets Personal About Improving Global Cancer Care for World Cancer Day
Nonprofit alliance behind gold standard oncology guidelines shares stories of personal connections to cancer that inspire many within the organization. Global oncology community looks at the impact from COVID-19 on cancer care over the past year. PLYMOUTH MEETING, Pa., Feb. 4, 2021 /PRNewswire/ ...
2021-02-04 08:05
2811
Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian® Linac
CLEVELAND, Feb. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Edogawa Hospital in Tokyo is the first hospital inJapan to treat patients with the MRIdian Linac System. Edogawa Hospital began treating patients in 2018 on the MRIdian cobalt system. The upgrade to MRIdi...
2021-02-04 07:43
7082
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
Not intended for distribution in the USA, Canada or UK - TEPMETKO is approved for both treatment naïve and previously treated MET ex14 positive NSCLC patients - TEPMETKO demonstrated consistent and durable responses in both treatment naïve and previously treatedMETex14 patients in the VISION stud...
2021-02-04 02:57
1518
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®)...
2021-02-03 23:45
5023
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
CHENGDU, China, Feb. 3, 2021 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong", SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept. The drug is an anti-VEGF fusion protein, approv...
2021-02-03 22:00
4122
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 3, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
2021-02-03 22:00
6427
Guardant360 CDx submitted for regulatory approval in Japan
TOKYO, Feb. 3, 2021 /PRNewswire/ -- Guardant Health Japan, an affiliate of Guardant Health Asia,Middle East & Africa (AMEA) has announced that it has submitted its application to the Ministry of Health, Labour and Welfare (MHLW) for regulatory approval of Guardant360 CDx, a liquid biopsy test for...
2021-02-03 18:41
2458
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-02-03 12:30
8938
Ping An Healthcare and Technology Company Limited posts revenue of RMB 6,866 million in 2020
Launches comprehensive strategic upgrade Revenue from online medical services, its core business, grows 82.4% year-on-year HONG KONG, Feb. 3, 2021 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; Stock Code: 01833.HK), a leading internet healthcare se...
2021-02-03 01:03
8024
Elekta's MOSAIQ and Versa HD earn top honors in 2021 Best in KLAS: Software and Services Report
ATLANTA, Feb. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that itsMOSAIQ® Oncology Information System (OIS) and Versa HD™ linear accelerator have been named "Best in KLAS" in the 2021 Best in KLAS: Software and Services Report. MOSAIQ was ranked first in the Oncology (Radiation) ca...
2021-02-03 00:30
3387
Latest Cigna International Markets Well-being Pulse Study Shows Global Populations Adapting but the COVID-19 Pandemic is Negatively Impacting People's Views of the Future
BLOOMFIELD, Conn., Feb. 2, 2021 /PRNewswire/ -- Cigna's (NYSE:CI) International Markets business has published its fourthCOVID-19 Global Impact Study. This series, which builds on Cigna's annual 360 Well-being Study, provides further insight into the global impact of the COVID-19 pandemic on peop...
2021-02-02 23:00
8865
Mindray Launches New BeneFusion e Series Infusion Systems, Delivering Efficiency in Every Droplet
SHENZHEN, China, Feb. 2, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global leader in the development of innovative healthcare technology, has unveiled its BeneFusion e Series, a revolutionary efficient infusion system for the healthcare industry. Available in three models, eSP, eVP and eDS,...
2021-02-02 21:17
4207
Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine
CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Feb. 2, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, announced today that the first healthy volunteer has been successfully dos...
2021-02-02 20:00
1601
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer
SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company recently released ...
2021-02-02 17:24
1630
Globally unique MRI Guarantee: The highest MRI safety with hearing implants from MED-EL
Worry-free, safe magnetic resonance imaging (MRI) with MED-EL cochlear, middle ear or bone conduction implants – now with lifetime guarantee. For immediate access to an MRI examination without surgery, discomfort or hearing downtime. INNSBRUCK, Austria, Feb. 2, 2021 /PRNewswire/ -- The innovative...
2021-02-02 15:00
1836
Inmagene launched U.S. subsidiary; Dr. Jean-Louis Saillot joined the company.
SAN DIEGO, Calif. and SHANGHAI, Feb. 2, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a leading biotech company focused on immunology-related therapeutic areas, today announced the launch of its wholly-owned subsidiary inSan Diego. Jean-Louis Saillot, MD has joined the company a...
2021-02-02 14:48
2115
Nippon Express (Thailand) Obtains GDP Certification for Domestic Transport Services
TOKYO, Feb. 2, 2021 /PRNewswire/ -- Nippon Express (Thailand) Co., Ltd. (hereinafter, "NE Thailand"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveTuesday, December 22, 2020, evidencing its compliance with stand...
2021-02-02 14:00
1211
Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA
SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (...
2021-02-02 12:11
3658
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 323 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
9824
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
8164
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
7735
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
7343
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
7008
